Homology Medicines's Total Assets for the quarter that ended in Dec. 2023 was $84.56 Mil.
During the past 12 months, Homology Medicines's average Total Assets Growth Rate was -96.40% per year.
During the past 3 years, the average Total Assets Growth Rate was -65.40% per year.
During the past 5 years, the average Total Assets Growth Rate was -35.30% per year.
During the past 8 years, Homology Medicines's highest 3-Year average Total Assets Growth Rate was 157.30%. The lowest was -65.40%. And the median was 8.00%.
The historical data trend for Homology Medicines's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Homology Medicines's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Homology Medicines (NAS:FIXX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Homology Medicines's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Homology Medicines Total Assets Related Terms
Thank you for viewing the detailed overview of Homology Medicines's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Homology Medicines (Homology Medicines) Business Description
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FIXX has been successfully added to your 